- Conditions
- Pulmonary Hypertension
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 376
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- macitentan (ACT-064992), placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 28 more
- Conditions
- Pediatric Pulmonary Hypertension
- Interventions
- No interventions / observations only
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 8 Years to 14 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Aurora, Colorado
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Placebo, Background PAH Therapy
- Biological · Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more
- Conditions
- Pulmonary Hypertension
- Interventions
- NX1011
- Drug
- Lead sponsor
- NITROX, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- PAH Therapies
- Other
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Brandon, Florida • Tampa, Florida • Chicago, Illinois + 12 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Remunity Pump for Remodulin
- Combination Product
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Morrisville, North Carolina
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- AV-101, Placebo
- Drug
- Lead sponsor
- Aerovate Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Usual Care, Home-based exercise program
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Pulmonary Hypertension
- Interventions
- Iloprost PD-6, Iloprost PD-15
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Inhalation Powder
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 12 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Esuberaprost, Placebo
- Drug
- Lead sponsor
- Lung Biotechnology PBC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 90 Years
- Enrollment
- 1,899 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2032
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Imatinib, Sildenafil, Bosentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Weston, Florida • Mineola, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- CT Pulmonary Angiography Scan
- Diagnostic Test
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- CT imaging, functional PET imaging
- Other
- Lead sponsor
- Robert Scott Harris, M.D.
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pulmonary Artery Hypertension
- Interventions
- reserpine, stellate ganglion block, lidocaine
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Hypertension, Pulmonary
- Interventions
- Riociguat (Adempas, BAY63-2521)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- La Jolla, California • Sacramento, California • Iowa City, Iowa + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- AV-101
- Drug
- Lead sponsor
- Aerovate Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 12 more
- Conditions
- Heart Failure, Pulmonary Arterial Hypertension
- Interventions
- right heart catheterization
- Diagnostic Test
- Lead sponsor
- Silverleaf Medical Sciences INC
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Pulmonary Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Pulmonary Arterial Hypertension - Lung Perfusion Scans
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York